Boehringer, Oxford University and Cumulus to explore brain activity in BPD
The NeuLogiq neuroassessment platform from Cumulus will be leveraged in the BPD patient population.
Drug Development
FDA approves AbbVie’s upadacitinib for giant cell arteritis
Construction begins on MSD’s $1bn biologics centre in Delaware, US
Small biotechs shoulder the burdens of an uncertain biopharma sector
Prilenia and Ferrer to commercialise pridopidine in Europe
Amgen to invest $900m in Ohio manufacturing facility
Granite Bio secures $100m in funding for new antibodies
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy
